Our first ex vivo development candidate, NTLA-5001, aims to treat #acutemyeloidleukemia using #CRISPR and engineering autologous T cell receptors directed towards the Wilms’ Tumor 1 (WT1) antigen. We anticipate entering the clinic this year: https://t.co/k1X2StcT6T https://t.co/rRZBqAnQoU